Showing results (161-170 of 233) with videos related to

Sort By:
Pageof 24
Blood|February 28, 2002
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cellsFenghuang Zhan, Johanna Hardin, Bob Kordsmeier, et al.
Blood Advances|September 1, 2023
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomesSheila K Pierson, Megan S Lim, Gordan Srkalovic, et al.
Blood|June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
The Journal of Clinical Investigation|June 1, 2021
TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignanciesCan Li, Jiliang Xia, Reinaldo Franqui-Machin, et al.
Blood Cancer Journal|November 7, 2025
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world studySamer Al Hadidi, Aniko Szabo, Bhavesh Mohan Lal, et al.
Haematologica|August 12, 2021
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease statusDavid Baker, Milan Bimali, Luis Carrillo, et al.
Frontiers in Immunology|April 4, 2025
Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patientsAllan Feng, Michael V Gonzalez, Muge Kalaycioglu, et al.
Haematologica|September 11, 2025
Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman diseaseAsami Nishikori, Midori Filiz Nishimura, Yoshito Nishimura, et al.
American Journal of Hematology|January 26, 2025
Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution PatternsMizuna Otsuka, Tomohiro Koga, Remi Sumiyoshi, et al.
JCI Insight|May 8, 2020
Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman diseaseRuth-Anne Langan Pai, Alberto Sada Japp, Michael Gonzalez, et al.
Pageof 24